Skip to main content

Contact Giuseppe Turchetti

From: Budget impact analysis of the use of extended half-life recombinant factor VIII (efmoroctocog alfa) for the treatment of congenital haemophilia a: the Italian National Health System perspective

Contact corresponding author
\